Back to Journals » Cancer Management and Research » Volume 11

TMED2 as a marker of prognosis in breast cancer [Letter]

Authors Schwarz MC, Allikmets S

Received 1 April 2019

Accepted for publication 28 June 2019

Published 11 July 2019 Volume 2019:11 Pages 6377—6378

DOI https://doi.org/10.2147/CMAR.S210756

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Nicola Ludin

Peer reviewer comments 2

Editor who approved publication: Dr Kenan Onel


Megan Catherine Schwarz,1 Silvia Allikmets2

1Icahn School of Medicine, Mount Sinai Oncological Sciences, New York, NY, USA; 2Faculty of Life Sciences & Medicine, GKT School of Medical Education, King’s College London, London, UK

We thank Lin et al for their interesting study proposing TMED2 overexpression as a potential marker of poor prognosis in breast cancer.1 While the results imply that TMED2 overexpression decreases survival rates, we are hesitant to agree with the authors’ statement claiming its prognostic power until certain aspects of the study are clarified. We further propose recommendations for consideration in future investigations to maximize the potential of this study.

View the original paper by Lin and colleagues



Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]